• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Ortenzio Robert A disposed of 3,070,367 shares and acquired 1,023,455 shares (SEC Form 4)

    3/4/25 4:59:26 PM ET
    $CON
    Medical Specialities
    Health Care
    Get the next $CON alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    ORTENZIO ROBERT A

    (Last) (First) (Middle)
    C/O CONCENTRA GROUP HOLDINGS PARENT, INC
    5080 SPECTRUM DRIVE, SUITE 1200W

    (Street)
    ADDISON TX 75001

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Concentra Group Holdings Parent, Inc. [ CON ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/03/2025 J(1) 3,070,367 D $0 0 I By the Rocco A. Ortenzio Separate Exempt Descendants Trust
    Common Stock 03/03/2025 J(2) 1,023,455 A $0 1,023,455 I The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio
    Common Stock 5,526,046 D
    Common Stock 1,032,115 I By the Robert A. Ortenzio Descendants Trust
    Common Stock 226,286 I By the Robert A. Ortenzio 2014 Trust for Bryan A. Ortenzio
    Common Stock 226,286 I By the Robert A. Ortenzio 2014 Trust for Kevin M. Ortenzio
    Common Stock 226,286 I By the Robert A. Ortenzio 2014 Trust for Madeline G. Ortenzio
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The Rocco A. Ortenzio Separate Exempt Descendants Trust transferred in the aggregate 3,070,367 shares of Company's common stock to the Rocco A. Ortenzio Separate Descendants FBO Robert Ortenzio, the Rocco A. Ortenzio Separate Descendants FBO John Ortenzio and the Rocco A. Ortenzio Separate Descendants FBO Martin Ortenzio. There was no consideration paid for such distribution.
    2. The reporting person received 1,023,455 shares of Company's common stock from the Rocco A. Ortenzio Separate Exempt Descendants Trust. The shares are held by the Rocco A. Ortenzio Separate Descendants Trust FBO Robert A. Ortenzio. There was no consideration paid for such distribution.
    /s/ Timothy Ryan, Attorney-in-Fact 03/04/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CON

    DatePrice TargetRatingAnalyst
    12/16/2024$24.00Neutral → Buy
    BofA Securities
    10/7/2024$30.50 → $24.00Buy → Neutral
    BofA Securities
    8/20/2024$33.00Outperform
    RBC Capital Mkts
    8/19/2024Buy
    BofA Securities
    8/19/2024$29.00Buy
    Deutsche Bank
    8/19/2024$29.00Overweight
    JP Morgan
    8/19/2024$32.00Buy
    Goldman
    8/19/2024$28.00Outperform
    Mizuho
    More analyst ratings

    $CON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ortenzio Robert A disposed of 3,070,367 shares and acquired 1,023,455 shares (SEC Form 4)

      4 - Concentra Group Holdings Parent, Inc. (0002014596) (Issuer)

      3/4/25 4:59:26 PM ET
      $CON
      Medical Specialities
      Health Care
    • Officer Mcandrew Douglas R. was granted 60,000 shares (SEC Form 4)

      4 - Concentra Group Holdings Parent, Inc. (0002014596) (Issuer)

      11/29/24 5:59:48 PM ET
      $CON
      Medical Specialities
      Health Care
    • Officer Kosuth Michael A. was granted 60,000 shares (SEC Form 4)

      4 - Concentra Group Holdings Parent, Inc. (0002014596) (Issuer)

      11/29/24 5:58:45 PM ET
      $CON
      Medical Specialities
      Health Care